CLRB Stock Surges 28.6% on $140M Financing and Positive Trial Data

Cellectar Biosciences, Inc. (NASDAQ: CLRB) delivered a strong performance on May 5, 2026, with CLRB stock surging 28.6% to $3.46 USD on heavy trading volume of 50.5 million shares. The biotech company announced an oversubscribed financing round raising up to $140 million, led by Nantahala Capital and supported by major healthcare funds. The capital raise comes alongside positive 12-month follow-up data from the Phase 2b CLOVER WaM trial for iopofosine I-131 in Waldenström macroglobulinemia patients. The trial demonstrated an 83.6% overall response rate and 61.8% major response rate in heavily pretreated populations. This combination of clinical validation and substantial funding positions Cellectar to advance toward FDA accelerated approval and launch a confirmatory trial in Q4 2026.

CLRB Stock Momentum Driven by Financing and Clinical Success

CLRB stock opened at $4.505 and traded between $3.17 and $4.70 during the intraday session. The 28.6% gain reflects investor confidence in both the company’s clinical pipeline and financial runway. Volume surged to 50.5 million shares, nearly 1,450% above the 30-day average of 34,888 shares, signaling strong institutional and retail participation.

The financing round was heavily oversubscribed, attracting participation from Balyasny Asset Management, Caligan Partners, Janus Henderson Investors, and SilverArc Capital Management. Executive management also participated, demonstrating internal confidence. This capital injection addresses the company’s cash burn and funds the critical Phase 2b confirmatory trial expected to begin in Q4 2026.

Phase 2b Trial Results Strengthen Regulatory Path for CLRB

The 12-month follow-up data from the CLOVER WaM study represents a major milestone for Cellectar’s lead candidate, iopofosine I-131. The trial achieved an 83.6% overall response rate and 61.8% major response rate in a heavily pretreated patient population with relapsed or refractory Waldenström macroglobulinemia.

Median duration of response reached 17.8 months, demonstrating durable clinical benefit. Post-BTKi patients showed particularly strong results with approximately 64% major response rates and responses exceeding 18 months. The FDA-requested dataset with 12-month follow-up strengthens regulatory positioning for accelerated approval, a critical pathway for rare blood cancers.

Market Sentiment and Trading Activity

Trading Activity: CLRB stock’s intraday volatility reflects the market’s reaction to dual catalysts. The stock recovered from a $2.69 previous close to reach $4.70 intraday high, capturing a 74.7% swing. This aggressive repricing indicates strong conviction among buyers that the financing and trial data justify higher valuations.

Liquidation: Despite the positive momentum, CLRB remains a speculative biotech play. The company carries a negative EPS of -$8.35 and trades at a negative PE ratio of -0.34, reflecting ongoing losses. However, the $140 million capital raise extends the runway significantly, reducing near-term dilution risk from future financings. The stock’s 52-week range of $2.43 to $20.70 shows extreme volatility typical of clinical-stage biotech companies.

CLRB Stock Valuation and Meyka AI Assessment

Meyka AI rates CLRB with a grade of B, suggesting a HOLD recommendation. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating reflects balanced risk-reward dynamics: strong clinical progress and capital support offset by negative profitability metrics and high execution risk.

Meyka AI’s forecast model projects CLRB stock reaching $5.16 USD within 12 months, implying 49% upside from current levels. Over five years, the model forecasts $12.96 USD, representing **274% potential appreciation. Track CLRB on Meyka for real-time updates on clinical milestones and financing developments. Forecasts are model-based projections and not guarantees. These grades are not guaranteed and we are not financial advisors.

Final Thoughts

Cellectar Biosciences surged 28.6% on May 5, 2026, following a $140 million financing and strong Phase 2b trial results showing 83.6% response rates in Waldenström macroglobulinemia patients. The capital provides runway through Q4 2026 trials, supporting accelerated approval potential. However, CLRB remains a clinical-stage biotech with execution and regulatory risks. The stock’s rally reflects optimism, but outcomes remain uncertain. Investors should size positions carefully given biotech volatility.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.